comparemela.com
Home
Live Updates
FDA Accepts BLA for Datopotamab Deruxtecan in Pretreated Advanced Nonsquamous NSCLC : comparemela.com
FDA Accepts BLA for Datopotamab Deruxtecan in Pretreated Advanced Nonsquamous NSCLC
A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.
Related Keywords
Ken Takeshita ,
Daiichi Sankyo ,
Susan Galbraith ,
Astrazeneca ,
Prescription Drug User Fee Act ,
Datopotamab Deruxtecan ,
Dato Dxd ,
Non Small Cell Lung Cancer ,
Nsclc ,
Lung Cancer ,
Biologics License Application ,
Tropion Lung01 Trial ,
comparemela.com © 2020. All Rights Reserved.